n-3 Polyunsaturated Fatty Acids After Coronary Artery Bypass Grafting Umberto Benedetto, MD, PhD, Giovanni Melina, MD, PhD, Roberta di Bartolomeo, MD, Emiliano Angeloni, MD, Davide Sansone, MD, Giulia Falaschi, MD, Fabio Capuano, MD, Cosimo Comito, MD, Antonino Roscitano, MD, Riccardo Sinatra, MD The Annals of Thoracic Surgery Volume 91, Issue 4, Pages 1169-1175 (April 2011) DOI: 10.1016/j.athoracsur.2010.11.068 Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions
Fig 1 Adjusted survival curves according to n-3 polyunsaturated fatty acid (PUFAs) supplementation among patients with good (hazard ratio, 0.89; 95% confidence interval, 0.65 to 1.01) and poor ventricular function (hazard ratio, 0.36; 95% confidence interval, 0.17 to 0.76). The Annals of Thoracic Surgery 2011 91, 1169-1175DOI: (10.1016/j.athoracsur.2010.11.068) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions
Fig 2 Major adverse cardiac and cerebrovascular event-free survival according to n-3 polyunsaturated fatty acid (PUFAs) supplementation among patients with good (hazard ratio, 0.64; 95% confidence interval, 0.41 to 0.92) and poor ventricular function (hazard ratio, 0.68; 95% confidence interval, 0.43 to 0.93). The Annals of Thoracic Surgery 2011 91, 1169-1175DOI: (10.1016/j.athoracsur.2010.11.068) Copyright © 2011 The Society of Thoracic Surgeons Terms and Conditions